EUVIMEDEUVIMED entdecken
Crossref

Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1 plus and Day 15 MRD positivity

Hsi-Che Liu iD, Ying-Jung Huang, Tang-Her Jaing, Kang-Hsi Wu, Shih-Hsiang Chen iD, Shih-Chung Wang, Ting-Chi Yeh iD, Chih-Cheng Hsiao, Te-Kau Chang, Hsiu-Ju Yen, Fang-Liang Huang, Pei-Chin Lin und 10 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Hsi-Che Liu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology-Oncology, MacKay Children's Hospital and MacKay Medical College, Taipei, Taiwan. Hauptthemen laut MEDLINE: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Mackay Memorial Hospital, Taiwan, Ministry of Health and Welfare, Taiwan, Chang Gung Memorial Hospital, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigates the potential utility of IKZF1 deletion as an additional high‐risk marker for paediatric acute lymphoblastic leukaemia (ALL). The prognostic impact of IKZF1 status, in conjunction with minimal/measurable residual disease (MRD), was evaluated within the MRD‐guided TPOG‐ALL‐2013 protocol using 412 newly diagnosed B‐ALL patients aged 1–18. IKZF1 status was determined using multiplex ligation‐dependent probe amplification. IKZF1 deletions, when co‐occurring with CDKN2A , CDKN2B , PAX5 or PAR1 region deletions in the absence of ERG deletions, were termed IKZF1 plus . Both IKZF1 deletion (14.6%) and IKZF1 plus (7.8%) independently predicted poorer outcomes in B‐ALL. IKZF1 plus was observed in 4.1% of Philadelphia‐negative ALL, with a significantly lower 5‐year event‐free survival (53.9%) compared to IKZF1 deletion alone (83.8%) and wild‐type IKZF1 (91.3%) ( p < 0.0001). Among patients with Day 15 MRD ≥0.01%, provisional high‐risk patients with IKZF1 plus exhibited the worst outcomes in event‐free survival (42.0%), relapse‐free survival (48.0%) and overall survival (72.7%) compared to other groups ( p < 0.0001). Integration of IKZF1 plus and positive Day 15 MRD identified a subgroup of Philadelphia‐negative B‐ALL with a 50% risk of relapse. This study highlights the importance of assessing IKZF1 plus alongside Day 15 MRD positivity to identify patients at increased risk of adverse outcomes, potentially minimizing overtreatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaChildHumansGene DeletionIkaros Transcription FactorNeoplasm Recurrence, LocalNeoplasm, ResidualPrognosisRisk AssessmentTranscription FactorsInfantChild, PreschoolAdolescent

Stichwörter der Autor:innen

IKAROSacute lymphoblastic leukemiachildhoodminimal/measurable residual disease

Substanzen

Ikaros Transcription FactorIKZF1 protein, humanTranscription Factors

Autor:innen und Institutionen

  • Department of Hematology-Oncology, MacKay Children's Hospital and MacKay Medical College, Taipei, Taiwan.
  • Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
  • Department of Hematology-Oncology, Chang Gung Children's Hospital at Linkou, Taoyuan, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Division of Pediatric Hematology-Oncology, Changhua Christian Children's Hospital, Changhua, Taiwan.

ORCID-Profile: Hsi-Che Liu, Shih-Hsiang Chen, Ting-Chi Yeh, Lee-Yung Shih

Förderung

  • Mackay Memorial Hospital, Taiwan
  • Ministry of Health and Welfare, Taiwan
  • Chang Gung Memorial Hospital, Taiwan
  • Ministry of Science and Technology, Taiwan
  • Mackay Memorial Hospital
  • Ministry of Health and Welfare
  • Chang Gung Memorial Hospital

Zitieren

APA

Liu, H. C., Huang, Y. J., Jaing, T. H., Wu, K. H., Chen, S. H., Wang, S. C., Yeh, T. C., Hsiao, C. C., Chang, T. K., Yen, H. J., Huang, F. L., Lin, P. C., Hou, J. Y., Sheen, J. M., Liao, Y. M., Chang, T. Y., Chen, Y. C., Chiou, S. S., Yang, C. P., …, & Shih, L. Y. (2024). Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1 plus and Day 15 MRD positivity. British Journal of Haematology. https://doi.org/10.1111/bjh.19338

Vancouver

Liu HC, Huang YJ, Jaing TH, Wu KH, Chen SH, Wang SC, et al. Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1 plus and Day 15 MRD positivity. British Journal of Haematology. 2024. doi:10.1111/bjh.19338

BibTeX
@article{Liu2024,
  author = {Liu, Hsi-Che and Huang, Ying-Jung and Jaing, Tang-Her and Wu, Kang-Hsi and Chen, Shih-Hsiang and Wang, Shih-Chung and Yeh, Ting-Chi and Hsiao, Chih-Cheng and Chang, Te-Kau and Yen, Hsiu-Ju and Huang, Fang-Liang and Lin, Pei-Chin and Hou, Jen-Yin and Sheen, Jiunn-Ming and Liao, Yu-Mei and Chang, Tsung-Yen and Chen, Yu-Chieh and Chiou, Shyh-Shin and Yang, Chao-Ping and Pui, Ching-Hon and Liang, Der-Cherng and Shih, Lee-Yung},
  title = {Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1 plus and Day 15 MRD positivity},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19338}
}
Kostenlos starten →